Clinical Trials Directory

Trials / Completed

CompletedNCT06550154

Association Between Oral Lichen Planus and Thyroid Disease

Association Between Oral Lichen Planus and Thyroid Disease: A Cross-sectional Study

Status
Completed
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
University of Barcelona · Academic / Other
Sex
All
Age
29 Years – 94 Years
Healthy volunteers
Accepted

Summary

The goal of this observational study is to determine the prevalence of thyroid disease in adults with oral lichen planus (OLP) treated at the Dental Hospital of the University of Barcelona (HOUB), and to evaluate the association between OLP and thyroid disease. Secondly, to assess the association between OLP and other comorbidities, including arterial hypertension, diabetes mellitus type 2, dyslipidemia, anxiety, and depression. The main question it aims to answer is: Do people with OLP have a significant risk of developing thyroid disorders compared to people without OLP?

Detailed description

A cross-sectional study was conducted to investigate a total of 120 participants, 60 patients with oral lichen planus and 60 patients without the history of OLP as a control group, attending at the Dental Hospital of the University of Barcelona (HOUB). The personal medical history of thyroid disease, demographic information (age and gender) and other comorbidities history information, were collected in both groups, and obtained through the GESDEN® healthcare software (Gesden G5, Infomed - Henry Schein®, New York, United States), in addition to the paper medical records (biopsy report). Data were analyzed using χ² test and simple binary logistic regression models with the SPSS® statistical software, version 29.0.2.0 for Windows (SPSS, Illinois, United States).

Conditions

Interventions

TypeNameDescription
OTHERData collectionParticipants were identified by reviewing electronic medical records. Medical history information of thyroid disease and associated medication were collected in both groups, as well as a history of other comorbidities such as diabetes mellitus type 2, arterial hypertension, dyslipidemia, anxiety, and depression. Cases and controls were matched by age and sex.

Timeline

Start date
2023-12-13
Primary completion
2024-04-17
Completion
2024-04-22
First posted
2024-08-12
Last updated
2024-08-12

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT06550154. Inclusion in this directory is not an endorsement.